Full Transcript Introduction to Microdosing 0:01 [music] Welcome to the trip lab kitchen table 0:05 conversations about integrative medicine and psychedelics. [music] 0:08 I'm your host and attending physician Dr. Mariela Wood. 0:14 Welcome back to the trip lab. So, we are finally doing a full episode on micro 0:18 doing psychedelics. This episode is definitely been coming for a long time. 0:22 And if you've listened to my other podcast about psychedelics, you know 0:25 that a lot of the neuroscience we've talked about up to this point has 0:29 focused on what I'll call the quote unquote big trips. So fulldo psychedelic 0:33 experiences, psychedelic assisted therapy, and the kinds of brain network 0:37 changes that happen when people undergo those more immersive states. So if 0:41 you're interested in those side of things, I definitely recommend going 0:44 back and listening to some of the earlier episodes where we really break 0:47 down what's happening in the brain during those type of experiences. But 0:51 micro doing is a totally different conversation and it's one that's been 0:54 circulating for a long time now. I would say that for a lot of people micro doing 0:58 feels more accessible. It feels less intense, less scary, and more compatible 1:03 with daily life. You don't have to step out of your routine. You don't have to 1:07 enter an altered state. And there's this idea that you might get some of the 1:10 benefits of psychedelics without the full intensity of a full trip. So people 1:14 are really interested in micro doing. And for a long time, the data just 1:18 wasn't that satisfying. Much of what the data did show came from personal 1:23 experience, observational reports, and a lot of enthusiasm, but not a lot of 1:27 highquality data. But now that is finally starting to change. In the last 1:31 few years, we've seen more controlled studies come out. So, better design 1:35 trials, more thoughtful analysis, and a clearer look at what micro doing might 1:40 be doing, what it might not be doing, and why the placebo response turns out 1:44 to be a pretty big part of this story. So, I thought this would be a perfect 1:48 time to do a full episode focused specifically on micro doing. So, what it 1:52 is, how it's different from a full psychedelic experience, what the current 1:56 science actually shows, and how the neuroscience helps explain why micro 2:00 dosing may or may not work the way that people hope it does. So, of course, 2:04 let's start at the beginning. What is micro doing? When people talk about 2:09 micro doing psychedelics, they're usually referring to taking a very small 2:12 amount of these substances, most commonly psilocybin or LSD. And the dose 2:18 is intended to be so low that you might not even be aware that you've taken a 2:21 psychedelic at all. There are no visual changes, no altered perception, no sense
What Microdosing Is and How It Differs from a Full Trip 2:27 of quote unquote dripping. And ideally, you're supposed to be able to go about 2:31 your day as usual. to go to work, take care of responsibilities, have 2:34 conversations, function normally without any obvious interruption to your 2:39 consciousness. So this is obviously very different from a full psychedelic trip. 2:43 With a full dose experience, you're intentionally entering an altered state. 2:48 There can be significant changes in perception, emotional processing, and 2:51 sense of self. Sometimes with visual changes, and also what people describe 2:55 as ego death or ego dissolution. From a neuroscience perspective, those larger 3:00 doses reliably disrupt dominant brain networks, especially the default mode 3:04 network, and temporarily increase global connectivity across the brain. That 3:09 network level disruption is part of why full dose psychedelic therapy has been 3:13 associated with profound shifts in perspective, insight, and in many cases 3:17 lasting improvements in mental health outcomes. So again, I talk about all of 3:21 this a lot in my previous podcast if you want to dive into those ones. Micro 3:25 doing does not appear to do all that. So the theory is that it might gently nudge 3:30 certain neurobiological systems. So perhaps influencing mood, focus, 3:34 creativity, or emotional flexibility without inducing that full altered 3:38 state. So essentially allowing those new 3:41 neuronal connections to form gradually over time may be similar to what a 3:45 long-term meditation practice can do for you. And we do know that even with micro 3:49 doses, they do act on those serotonin receptors still. So possibly creating 3:54 those same shifts but just on a much smaller scale. But the data is 3:58 significantly different as far as outcomes compared to a full psychedelic 4:01 trip. So we'll definitely dive into those studies. But first I want to jump 4:04 into the current micro doing landscape and why it has gotten so much hype. 4:08 Culturally micro doing really started gaining traction in the early 2010s. So 4:13 not through medicine specifically but through personal experimentation. 4:17 It circulated first through creative communities, tech culture, and people 4:21 interested in self-optimization. And I definitely do see the appeal. You 4:26 get subtle benefits without the intensity, time commitment, or 4:29 psychological risk of a full psychedelic experience. I think one of the more 4:33 prominent shifts happened when James Fatiman, a psychologist, published the 4:36 psychedelic explorers guide in 2011. In this book, he presented this exploratory 4:41 practice, and he actually included micro doing protocols. I will say largely made 4:46 by anecdotal reports and self-experimentation rather than true 4:49 literature. But many people still adopt their micro doing protocols from that 4:53 book today. So after that book came out, micro doing really took on a life of its 4:57 own. People began sharing personal stories with improved mood, better 5:02 focus, increased creativity and more emotional release. And those stories 5:06 spread fast. I'll say much faster than the science did at that time. So over 5:11 time micro doing became embedded in wellness culture, productivity culture 5:15 and eventually even clinical adjacent spaces as well. And today content around 5:19 micro doing is very widely available. We now have dozens of online micro doing 5:24 protocols, coaching programs and certifications, highly specific 5:28 schedules, stacks and dose claims, and a growing sense that micro doing is a 5:33 legitimate therapeutic intervention. But let's make a very important note here. 5:37 Many of the claims being made are primarily observational, 5:41 not necessarily grounded in hard scientific evidence. Now, I don't think 5:45 that this discounts micro doing at all, but I do want to note that before we get 5:49 into the theories behind how micro doing work. So, let's get into that fun part, 5:54 a little exploration into how micro dosing might actually work, even though
Why Microdosing Became Popular 5:57 this has not fully been proven yet in the literature. So, we often talk about 6:01 full trips as a brain reset. So with that we can think about micro doing as a 6:06 sort of very light tap on the system. So instead of disrupting dominant networks 6:11 it may subtly shift how certain circuits communicate almost like turning a dial 6:16 rather than flipping a switch completely. And at the receptor level 6:19 psychedelics primarily act on the serotonin receptors especially the 6:23 serotonin 2a receptor. Fulldo psychedelics strongly activate these 6:27 receptors and trigger widespread changes in cortical signaling. With micro doing 6:32 the activation is much more modest, but that doesn't necessarily mean it's 6:35 meaningless. Even small changes in serotonin signaling can influence things 6:40 like mood regulation, cognitive flexibility, emotional salience, and how 6:44 we allocate attention. So, sort of, but not completely like how our 6:49 anti-depressant SSRIs might work. SSRIs are definitely different from micro 6:53 doing. They inhibit the reuptake of serotonin instead of adding something 6:56 new to the system, but there is some overlap. Another way to think of micro 7:00 doing is in terms of neural gain. So that's the idea that the brain can 7:05 amplify or dampen signals depending on context. 7:09 Micro doing might increase the gain just enough that internal experiences feel a 7:13 bit more vivid or accessible without tipping into a full altered state. This 7:18 also taps into the idea of plasticity priming. So full do psychedelics appear 7:22 to open windows of heightened plasticity. So periods where the brain 7:26 is more malleable and responsive to experience with micro doing this effect 7:30 if it exists may be far subtler. So instead of opening a big window it might 7:35 crack the door just slightly. So this could mean that what really matters 7:38 isn't just the dose itself but what you're doing while the system is in that 7:42 slightly more receptive state. So your environment, your mindset, your habits 7:47 and your intentions. And that also brings us to another possibility micro 7:52 doing as a salance modulator. So rather than changing the content of 7:57 thought, micro doing may change what feels worth paying attention to. So 8:01 people do often describe noticing small things more. So their emotions, their 8:05 reactions, their surroundings. Those findings, it appears, doesn't require a 8:10 full hallucination or trip or a full network collapse. It just requires a 8:14 subtle shift in how the brain assigns meaning. So in that sense, micro dosing 8:19 may be less about adding something new to the brain and more about loosening 8:23 the grip of the autopilot. Just enough to notice what's already there. And of
How Microdosing Might Work in the Brain 8:27 course, all of this sits on top of context, expectation, intention, ritual, 8:33 and narrative likely interact with these neurobiological effects in very powerful 8:38 ways. If the brain is even slightly more plastic or receptive, then belief and 8:42 attention can do a lot of work. So when people say micro doing helped them feel 8:47 more creative, more connected or more motivated, it may not be that the 8:51 molecule is doing something dramatic on its own, but that it's creating a stage 8:56 where meaning, attention, and behavior are more easily shaped. This is also why 9:00 micro doing might feel transformative for some people, but overwhelming for 9:05 others. If the effect is subtle, then the context really matters. In fact, I 9:10 would say it becomes everything. And with that, that sets us up perfectly for 9:13 the next part of the story. Because if expectation and meaning play such a 9:17 large role here, then we have to talk about the placebo response. So not as a 9:23 flaw in the science, but as in my opinion one of the most powerful 9:26 neurobiological phenomena we have. So as this relates to micro doing, a lot of 9:31 the micro doing literature so far has shown that micro doing performs about as 9:36 well as placebo. And we'll get into those studies in more detail in a moment 9:40 here. But before we do, I want to pause here and take a little detour into the 9:44 placebo response itself. Because if we're being completely honest here, the 9:48 placebo response may be the closest thing modern medicine has to a 9:52 scientific description of magic. For a long time, placebo was treated like a 9:56 nuisance variable. So something to control for, something to subtract out 10:00 so that we could get the quote unquote real effect of a drug. But over the past 10:04 few decades, it's become very clear that the placebo isn't nothing. It's not 10:09 something to be controlled for. It's very real and we might be able to look 10:13 at it as a therapeutic mechanism rather than something to just control for in a 10:17 study. And this is because we have seen actual changes in the mind and the body 10:21 under what we call the placebo response. So we've seen reductions in pain, 10:26 indogenous opioid system activation, changes in stress hormones, and changes 10:31 in immune signaling. We've also seen actual motor changes in people, 10:35 particularly in patients with Parkinson's disease, when they believe 10:38 they're receiving a specific treatment, even if they're not. So, let's look at 10:42 that pain example. Functional MRI studies show that when patients are 10:46 given a placebo, but told that it is a pain med, we actually see decreased 10:52 activity in pain processing regions of the brain like the anterior singulate 10:55 cortex, the insula, and other brain networks. These are the same regions 11:00 that quiet down when someone actually receives a pain med. So this tells us 11:04 that this is not just a perception of decreased pain. The body is actually 11:09 processing pain less. So that's fascinating. But I think the next part 11:14 is even more fascinating. So the next part of that study is that when 11:18 researchers actually gave an opioid blocker medication, so a medication that 11:22 actually prevents the opioids from reaching the receptors, so thus not 11:26 allowing them to give pain control, something very interesting happened 11:30 again to the people who were given a placebo, not an actual pain medication. 11:35 So this is essentially what happened. Researchers gave the patients a fake 11:39 pill, told them it was a pain med. Patients reported the pain went away and 11:45 we saw the brain's indogenous or internal opioid production activate. 11:50 Then the researchers gave them an opioid blocker without telling them. That part 11:54 is the key. And patients reported that their pain returned. So this tells us 11:59 that actual opioids were released from the body when a placebo was given. If 12:04 that alone doesn't blow your mind, then I don't know what to tell you next. But 12:07 let's move on. I also want to look at Parkinson's disease as an example as 12:11 well because Parkinson's disease is characterized in large part by dopamine 12:16 deficiency. So I think this makes it a really useful condition to study the 12:20 placebo effect because we can actually measure dopamine release directly. So in 12:24 several well-designed studies, patients with Parkinson's disease were given a 12:28 placebo and told it was an active Parkinson's medication. When researchers 12:32 looked at what happened in the brain using PET imaging, they saw increased 12:36 dopamine release in the strriatum, the same region targeted by Parkinson's
The Placebo Response and Mind-Body Effects 12:41 medications. And the patients actually had decreased 12:45 tremors and improvement with movement without a drug. So I think what's 12:50 remarkable here isn't that the placebo didn't just change the subjective 12:54 experience, which it did. It actually triggered the release of the exact 12:58 neurotransmitter that the disease is defined by. So the brain responded to 13:02 expectation by producing more of what it was missing. So I think this is one of 13:07 the clearest demonstrations we have that belief in expectation can engage very 13:12 specific neurochemical systems. So not just very vague feel-good pathways but 13:17 actual specific biology. And this also helps us describe why mindbody medicine 13:22 makes real mechanistic sense. So from a mindbody medicine perspective, the brain 13:27 is constantly integrating information about the body, the environment, and 13:31 what it expects to happen next. So symptoms like pain, fatigue, mood, and 13:36 even motor function aren't generated in isolation. They're shaped by prediction, 13:41 interpretation, and context. So when the brain even anticipates that relief is 13:46 coming in general or because a person was given a placebo and told it was 13:50 real, the brain actually changes signaling that influences autonomic 13:55 tone, neuroindocrine signaling, immune activity, and neurotransmitter release. 14:00 So if we really want to talk about the placebo as a therapeutic mechanism, 14:04 we're talking about the brain's capacity to influence bodily systems through top- 14:08 down control. So, we're essentially inducing a mindbody medicine connection 14:12 with an actual or fake pill. And this is why placebo matters so much in the micro 14:17 doing conversation. If micro doing is producing subtle or inconsistent 14:21 pharmological effects, but it's embedded in a context of strong expectation, 14:26 intention, and narrative, then the placebo response may account for a 14:30 significant portion of the benefit people report. So with that little dip 14:34 into understanding the placebo response, let's jump back into the latest micro 14:38 doing studies. So early studies were mostly observational, meaning people 14:43 micro dosed on their own and then reported what happened. People reported 14:47 a lot of things from increased creativity in increased productivity, 14:51 more meaning, less depression, less anxiety, a whole lot of things. So 14:55 clearly we see why there was some interest in studying micro doing more. 14:59 Researchers then tried to build a placeboc controlled trial into this real 15:02 world micro doing culture and I think the most well-known or famous study was 15:06 published in EIFE in 2011. So participants were asked to prepare 15:10 capsules at home and some had a micro dose and summer placebo and then they 15:15 used a system so that they wouldn't know which weeks they were taking what until 15:18 the end. Researchers then tracked mood and psychological outcomes over about a 15:22 month and found that mood and well-being improved during the micro doing weeks 15:27 and the placebo weeks. So, some people did view this study as essentially quote 15:32 unquote debunking micro doing as an effective tool. But now we're actually 15:36 seeing this as something more. Whatever micro doing is or is not doing, it is 15:41 hugely impacted by expectancy, context, and the participation itself. A 2024 15:47 review that pulled together controlled micro doing studies made a key 15:51 distinction that I think is the most honest way to interpret the field. So 15:55 acute effects versus repeated dosing outcomes in controlled settings. Low 16:00 doses of LSD, so about 10 to 20 micrograms, can produce perceptual acute 16:05 effects in some people. So this might include subtle shifts in mood, social 16:09 processing, or physiology. But when researchers looked at what happened with 16:13 repeated dosing over time, the results do not reliably show sustained 16:17 improvements in mood or cognition compared to placebo. Then finally 2025, 16:22 we got something the field really needed. So a proper clinical population 16:26 trial. So a randomized double blind placeboc controlled phase 2a trial was 16:31 published in JAMAMA psychiatry and they tested repeated lowd dose LSD in adults 16:36 with ADHD. So 20 micrograms twice a week for 6 weeks. And here's what happened. 16:41 ADHD symptoms improved again in both groups. The placebo group improved and 16:48 the LSD group improved and there was no meaningful difference between the two 16:52 groups. The study did show that repeated lowd dose LSD was generally well 16:56 tolerated in the outpatient setting which is important but it failed their 17:00 key test. It was not more effective than placebo for ADHD symptoms specifically. 17:06 I think that trial is important because it's probably the cleanest, most 17:09 clinically relevant example of what we keep seeing. Micro doing has shown to be 17:14 safe in controlled settings and people do feel better over time, but it's 17:18 difficult to say that the molecule itself is outperforming just regular 17:23 expectation in context. On the psilocybin side of things, we're finally
What the Latest Studies Show 17:27 seeing more rigorous placeboc controlled longitudinal work, too. In 2025, a 17:32 report was published from the results of two double blind placeboc controlled 17:35 longitudinal trials looking at cognitive and subjective effects of psilocybin 17:40 micro doing. And their bottom line conclusion again was essentially the 17:44 same. No reliable enhancement of cognitive or emotional functioning 17:48 beyond placebo. And zooming out a little bit further, in 2025, a pre-registered 17:54 meta analysis looked across micro doing studies on cognitive outcomes. So they 17:58 looked at 14 studies with over 1,600 participants and again found no overall 18:04 cognitive enhancement compared to the placebo. Interestingly they also did 18:08 find evidence of an actual decrease in cognitive control. So meaning that micro 18:13 doing may not be the productivity upgrade it's often marketed as. So 18:16 overall you see why I prefaced these studies with an explanation of the 18:20 placebo response. Because right now studies show that micro doing is not 18:25 more effective than the placebo. But does that make micro dosing useless? I 18:30 certainly don't think so. I think these studies have done a couple things. One, 18:34 they have further proved the therapeutic potential of the placebo response. And 18:39 two, I think the theory behind micro doing beyond the placebo response is 18:43 still very interesting and warrants more studies because what these studies 18:47 largely tested was whether micro doing works, not how it might work. And most 18:53 of the trials so far have not been designed to rigorously interrogate the 18:57 underlying neurobiology. They're mainly focused on self-report outcomes over 19:01 relatively short time frames, I will add, not on neural signaling, plasticity 19:06 markers, or network level changes that might be subtle, cumulative, or context 19:10 dependent. So, I think it's still possible that micro doing exert a small 19:14 biological effect that is just difficult to detect using our current tools or 19:20 that those effects really matter in certain contexts, populations, or when 19:24 paired with specific behaviors or environments. And I think it's also 19:27 important to note that from a neuroscience perspective, the hypothesis 19:31 has never really been that micro doing recreates the effects of a full 19:34 psychedelic experience. It's that very low doses might slightly modulate 19:38 serotoninergurgic signaling, neural gain or salience in ways that could prime the 19:43 system, making attention, learning or habit change a little easier over time. 19:49 And those are things that are hard to measure, and we just don't have the kind 19:52 of rigorous mechanistic studies we needed to confirm or refute them yet. 19:56 So, at this point, I think the most accurate conclusion is not that micro 19:59 doing work, but that we don't yet have evidence that it works beyond placebo. 20:04 and we don't yet have the data to fully test the theories of how it might work. 20:08 So, this brings us to the question that a lot of you are probably asking by now. 20:12 Should you micro dose? Before I answer that, I'm going to preface that this 20:16 podcast is not medical advice. This is not me as a physician giving you 20:20 personal medical advice. This is for education purposes only and you should 20:25 always consult with your personal physician before making any health 20:28 decisions. But going back to the question, should people micro dose? 20:32 based on the studies. Maybe, maybe not. It might work, it might not. Many people 20:38 do report meaningful benefits. Again, observational reports, not medical data. 20:43 But others also feel nothing. And based on the best evidence we have right now, 20:47 micro dosing does not consistently outperform placebo on outcomes like 20:50 mood, cognition, or clinical symptoms. That doesn't mean that people aren't 20:55 experiencing real changes. But it does mean that we can't confidently attribute 20:59 those changes to the pharmarmacology alone. Also important to be clear here 21:03 about boundaries. Psychedelics and micro doing psychedelics is not FDA approved. 21:09 These substances are not regulated, not standardized, and not legally 21:13 prescribable in most settings. That means that there are concerns around 21:17 safety, dosing variability, purity, drug interactions, and legal risk, especially 21:22 if you're doing micro doing outside of a research setting. So keep all of that in 21:26 mind when you're pondering that question. But if you still are pondering 21:29 micro doing, I think it's worth asking a deeper question first. What are you
Should You Microdose? Risks, Limits, and Alternatives 21:35 actually hoping it will change? Is it mood, focus, creativity, 21:41 emotional flexibility, or a sense of openness? 21:45 Because when we look closely at the science, many of the reported benefits 21:49 of micro doing overlap with mechanisms we already know how to engage with 21:54 without substances through mindbody practices. From what we understand about 21:58 the placebo response, expectation and top- down regulation, practices that 22:04 involve intention, ritual, and attention can meaningfully change physiology. So 22:10 things like mindfulness, meditation, breath work, journaling, psychotherapy 22:16 of course, movement practices like yoga or chiong, time spent in nature, and 22:22 even structured habit change all engage the systems that placebo responses rely 22:27 on. So prediction, meaning and nervous system regulation. So to conclude, I 22:32 think the most honest place to land in this whole landscape is this. Micro 22:37 doing remains an open scientific question. The current hype has certainly 22:42 outpaced the data for now, but we are certainly on a journey to understand 22:46 these molecules and all of their implications, whether that be large 22:50 therapeutic trips or micro doing self experiments. 22:54 And I think the most fascinating part, these molecules are asking us to 22:59 understand the mind and consciousness on more levels than neuroscience currently 23:03 grasps. Thanks for listening to the trip lab. If 23:08 you liked this episode, please subscribe and share so we can get the conversation 23:12 started about integrative medicine and psychedelics to destigmatize it and 23:16 fully explore what this could mean in the world. [music]
Comments